Prosecution Insights
Last updated: April 19, 2026
Application No. 18/296,538

ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME

Non-Final OA §102
Filed
Apr 06, 2023
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rohm And Haas Electronic Materials Korea Ltd.
OA Round
4 (Non-Final)
71%
Grant Probability
Favorable
4-5
OA Rounds
2y 11m
To Grant
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
869 granted / 1225 resolved
+10.9% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1268
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1225 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 27, 2026 has been entered. Response to Amendment and Rebuttal Arguments 3. The amendments to the claims and rebuttal arguments filed on February 27, 2026 have been fully considered. The outstanding ground of rejection has been obviated and is thus withdrawn. 4. Pursuant MPEP 803.02 the search and examination was extended. Prior art was found that anticipates the amended Markush claims. Therefore, the claims were rejected and claims to nonelected species were held withdrawn from further consideration. The claims were further searched to the extent of the full scope of claim 5 and additionally to the nonelected species shown below. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 5. Claim(s) 1 and 6-8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN2135446-05-6 ( PNG media_image1.png 268 546 media_image1.png Greyscale ). The reference has a publication date of October 17, 2017 which antedates the present claims having an effective filing date of October 27, 2017 based on priority claim to KR 20170140855. The compound corresponds to the present claims in the following manner: HTG=pyridine; L=bond; Ar1=phenyl; X1=X3=C; X2=N; Ar2=substituted aryl. 6. Claim(s) 1, 2 and 6-8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2101733-61-1 ( PNG media_image2.png 588 720 media_image2.png Greyscale ). The reference has a publication date of July 11, 2017 which antedates the present claims having an effective filing date of October 27, 2017 based on priority claim to KR 20170140855. The compound corresponds to the present claims in the following manner: HTG=substituted heteroaryl; L=bond; Ar1=phenyl; X1=N; X2=X3=C; Ar2=substituted pyrimidine. 7. Claim(s) 1- 3 and 6-8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 1267981-38-3 ( PNG media_image3.png 460 826 media_image3.png Greyscale ). The reference has a publication date of March 10, 2011 which antedates the present claims having an effective filing date of October 27, 2017 based on priority claim to KR 20170140855. The compound corresponds to the present claims in the following manner: HTG=substituted heteroaryl; L=phenyl; Ar1=substituted aryl; X1-X3=C; Ar2=phenyl. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 06, 2023
Application Filed
Jul 02, 2024
Non-Final Rejection — §102
Jan 08, 2025
Response Filed
Mar 16, 2025
Final Rejection — §102
Jun 19, 2025
Response after Non-Final Action
Jul 07, 2025
Request for Continued Examination
Jul 09, 2025
Response after Non-Final Action
Sep 29, 2025
Final Rejection — §102
Feb 27, 2026
Request for Continued Examination
Mar 09, 2026
Response after Non-Final Action
Mar 21, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595251
AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS
2y 5m to grant Granted Apr 07, 2026
Patent 12594266
TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OR PREVENTION OF PNEUMOCYSTIS SPP. PNEUMONIA
2y 5m to grant Granted Apr 07, 2026
Patent 12583854
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583855
RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583821
SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

4-5
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.4%)
2y 11m
Median Time to Grant
High
PTA Risk
Based on 1225 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month